ALX Oncology Holdings Inc.
HealthcareNASDAQ:ALXO · NASDAQ Global Select
+$0.06 today
Vol 0.64M · Avg 1.01M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $32.3M |
| Short-term Investments | $108.0M |
| Other Current | $5.2M |
| Total Current Assets | $145.6M |
| PP&E (Net) | $1.1M |
| Long-term Investments | $28.8M |
| Other Non-current | $2.9M |
| Total Non-current Assets | $32.8M |
| Total Assets | $178.3M |
Analysis
Selected assets total $178.3M for Latest. The largest visible component is Short-term Investments at $108.0M, about 60.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.4M -6.8% | $17.6M -21.6% | $22.4M -54.1% | $48.8M -86.6% | $363.7M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $28.4M -74.2% | $110.2M -31.3% | $160.3M -26.2% | $217.4M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $298.0K -66.6% | $892.0K | $0 | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $5.6M -1.1% | $5.7M -3.7% | $5.9M +24.4% | $4.8M | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $50.7M -62.2% | $134.4M -28.8% | $188.7M -30.4% | $271.0M -26.2% | $367.0M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $1.2M -87.5% | $9.6M -11.2% | $10.8M +10.5% | $9.8M +182.6% | $3.5M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $3.5M -0.9% | $3.5M -90.0% | $35.4M +112.1% | $16.7M | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $3.6M +1257.7% | $267.0K -96.5% | $7.6M -15.2% | $9.0M -7.1% | $9.7M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $8.3M -38.0% | $13.4M -75.1% | $53.9M +51.7% | $35.5M +169.8% | $13.2M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $59.0M -60.0% | $147.8M -39.1% | $242.6M -20.9% | $306.5M -19.4% | $380.2M | $13.3B | $11.9B | $10.6B |
| Account Payables | $4.9M +9.3% | $4.5M -47.7% | $8.6M +6.4% | $8.1M +114.5% | $3.8M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $5.2M +1099.3% | $435.0K | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $14.4M +141.7% | $6.0M -10.9% | $6.7M +42.0% | $4.7M +33.6% | $3.5M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $24.6M +32.7% | $18.5M -48.6% | $36.0M +27.1% | $28.3M +85.2% | $15.3M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 -100.0% | $9.5M -1.8% | $9.6M +2.7% | $9.4M | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $8.5M +729.6% | $1.0M -15.8% | $1.2M -77.1% | $5.3M +188.8% | $1.8M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $8.5M -45.6% | $15.7M -7.0% | $16.8M +14.6% | $14.7M +699.3% | $1.8M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $33.1M -3.2% | $34.2M -35.4% | $52.8M +22.8% | $43.0M +151.1% | $17.1M | $14.7B | $3.7B | $9.6B |
| Common Stock | $54.0K +1.9% | $53.0K +6.0% | $50.0K +22.0% | $41.0K +0.0% | $41.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$722.8M -16.4% | -$621.1M -27.7% | -$486.3M -49.4% | -$325.5M -61.1% | -$202.0M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $28.0K -89.8% | $275.0K +7.4% | $256.0K +130.3% | -$845.0K | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $26.0M -77.1% | $113.6M -40.1% | $189.7M -28.0% | $263.5M -27.4% | $363.0M | $9.1B | $7.7B | $3.3B |
| Total Debt | $5.2M -69.3% | $17.0M -1.3% | $17.2M +64.9% | $10.4M +1305.7% | $742.0K | $724.2M | $410.6M | $399.4M |
| Net Debt | -$11.2M -1794.1% | -$589.0K +88.7% | -$5.2M +86.4% | -$38.4M +89.4% | -$362.9M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Sutro Biopharma, Inc.
NASDAQ:STRO
$278.70M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$211.08M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Repare Therapeutics Inc.
RPTX
$114.24M
Adverum Biotechnologies, Inc.
ADVM
$96.26M
Precision BioSciences, Inc.
NASDAQ:DTIL
$78.25M
Biomea Fusion, Inc.
NASDAQ:BMEA
$69.61M
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
$61.36M
Metagenomi, Inc. Common Stock
MGX
$45.18M
aTyr Pharma, Inc.
ATYR
$43.18M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does ALXO have?
ALX Oncology Holdings Inc. (ALXO) reported $16.37M in cash and equivalents in fiscal 2025.
How much debt does ALXO carry?
ALX Oncology Holdings Inc. (ALXO) reported $5.22M of total debt, with net debt of -$11,156,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.